title: Innovative application of immunologic principles in heart transplantation.
abstract: BACKGROUND
  Each year, approximately 2,200 heart transplants are performed in the United States. As our understanding of the immune system grows, new tools are being developed to find compatible organ donors and to help with immune surveillance after transplantation. The purpose of this article is to review 3 of these techniques: the virtual crossmatch, the Cylex ImmuKnow assay, and the AlloMap test.
  
  
  METHODS
  Two authors (S.A.M. and J.C.) independently performed a literature search with the PubMed database using the key words ImmuKnow, Allomap, and virtual crossmatch in conjunction with heart transplantation. Articles were selected for inclusion if they had a primary focus on the use of virtual crossmatch in heart transplantation, the Cylex ImmuKnow assay, and the AlloMap test. Articles were not excluded on the basis of sample size but were excluded if they did not include heart transplant patients.
  
  
  RESULTS
  The virtual crossmatch is a technique that is being used successfully in heart transplant candidates to predict compatibility of donor organs by comparing the potential recipient's HLA-specific antibodies with the HLA type of the prospective donor. The ImmuKnow assay is a noninvasive blood test that measures the strength of immune activity, allowing clinicians to predict risk of infection and possible rejection in heart transplant patients. The AlloMap test is a noninvasive test that quantifies intracellular mRNA levels in mononuclear cells in peripheral blood samples using real-time polymerase chain reaction; this test has been shown to distinguish the dynamic changes in gene expression that occur in the presence or absence of acute cellular rejection.
  
  
  CONCLUSIONS
  As the science of transplant immunology advances, transplant cardiologists are taking advantage of the growing fund of knowledge to help their sensitized transplant candidates increase their chances of finding a compatible donor heart and are using commercially available tests to monitor the immune system and rule out rejection after transplantation.
authors: Stacy A
authors: SA
authors: Mandras
authors: Joaquin
authors: J
authors: Crespo
authors: Hamang M
authors: HM
authors: Patel
references: Pediatr Transplant. 2006 Feb;10(1):38-41
references: 16499585
references: Transplantation. 2006 Sep 15;82(5):663-8
references: 16969290
references: J Heart Lung Transplant. 2010 May;29(5):504-8
references: 20133166
references: J Heart Lung Transplant. 2009 Mar;28(3):213-25
references: 19285611
references: J Heart Lung Transplant. 2007 Apr;26(4):403-6
references: 17403484
references: Transplantation. 2006 Apr 15;81(7):1049-57
references: 16612283
references: Pediatr Transplant. 2007 Sep;11(6):650-4
references: 17663689
references: Clin Transplant. 2003 Apr;17(2):77-88
references: 12709071
references: Am J Transplant. 2006 Jan;6(1):150-60
references: 16433769
references: J Heart Lung Transplant. 2009 Aug;28(8):838-42
references: 19632582
references: Transplantation. 2003 Jan 15;75(1):43-9
references: 12544869
references: J Heart Lung Transplant. 2010 Jul;29(7):728-30
references: 20363155
references: J Heart Lung Transplant. 2007 Aug;26(8):769-81
references: 17692781
references: N Engl J Med. 2010 May 20;362(20):1890-900
references: 20413602
references: J Immunotoxicol. 2007 Jul;4(3):209-17
references: 18958730
references: J Heart Lung Transplant. 1995 Sep-Oct;14(5):856-64
references: 8800720
references: Transplant Rev (Orlando). 2009 Oct;23(4):235-47
references: 19778695
references: Am J Transplant. 2006 Oct;6(10):2307-15
references: 16939516
references: J Heart Lung Transplant. 2009 Nov;28(11):1129-34
references: 19782589